AMGN Amgen Inc.

192.07
-5.46  -3%
Previous Close 197.53
Open 195.04
Price To Book 8.53
Market Cap 122390700195
Shares 637,219,244
Volume 2,977,191
Short Ratio
Av. Daily Volume 3,007,060

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181148236
  2. 8-K - Current report 181147032
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 18972830
  4. 8-K - Current report 18972062
  5. 8-K - Current report 18971909

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Asthma
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Corlanor
Chronic Heart Failure
Approval announced May 17, 2018.
Erenumab
Migraine
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Approval announced December 1, 2017.
Repatha
Cardiovascular disease
sBLA approval announced January 5, 2017.
XGEVA
Multiple Myeloma
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
BLINCYTO
Ph+ R/R ALL
Phase 3 enrolling.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
BLA filing announced July 31, 2017.
ABP 980
Herceptin biosimilar
Phase 3 data released June 27, 2018 confirmed non-inferiority compared to infliximab, could not rule out superiority.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Parsabiv
Secondary hyperparathyroidism (SHPT)
CRL issued July 16, 2017. BLA filing resubmission announced July 13, 2018. Advisory committee meeting January 16, 2019.
EVENITY (Romosozumab)
Osteoporosis
Phase 2 data due by end of 2018.
AMG 301
Migraine
Phase 1 data at ASH December 2018 noted 7/42 CRs
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)

Latest News

  1. Better Buy: Biogen vs. Amgen
  2. FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
  3. 12 Stocks You Should Never Sell
  4. 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
  5. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  6. Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
  7. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  8. Amgen (AMGN) Gains But Lags Market: What You Should Know
  9. Why Arrowhead Pharmaceuticals Surged 11% Higher Today
  10. Do Analysts See Any Upside for Regeneron Stock?
  11. What Regeneron Pharmaceuticals’ Bottom Line Indicates
  12. Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript
  13. Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
  14. Understanding Seattle Genetics’ Operational Performance
  15. What Seattle Genetics’ Bottom-Line Trend Indicates
  16. How’s Seattle Genetics Positioned?
  17. Understanding Regeneron Pharmaceuticals’ Operational Performance
  18. Regeneron Pharmaceuticals’ Gross Margin Trends
  19. Entera shares jump 11.5% on news of collaboration with Amgen
  20. See what the IHS Markit Score report has to say about Amgen Inc.